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Abstract 
Pneumocystis jirovecii causes fungal pneumonia in immunocompromised 
patients and can be fatal if left untreated. The global mortality rate is 
estimated to be over 200 000 in AIDS patients. In non-AIDS patients there is 
an estimated mortality rate of 50 000 cases. This rate is increasing in 
developed countries, attributed to an increase in disorders which require 
immunotherapy. These include hematologic malignancies, organ transplant, 
inflammatory disorders and pre-existing lung disease. 
Immediate immunity is initiated by receptors that recognize pathogen 
associated molecular patterns on the surface of pathogenic fungi. 
Specifically, C-type lectin receptors (CLRs) have been shown to be the 
principal initiators of innate immune response during fungal infection. Limited 
studies have focused on the role of CLRs in Pneumocystis infection. Dectin- 
1and Mincle have been shown to recognise Pneumocystis surface antigens 
with Dectin-1 recognizing β-glucans on the Pneumocystis cell wall leading to 
an effective immune response. However, the role of a newly described CLR, 
the Dendritic Cell Immunoactivating Receptor (DCAR) remains undefined. 
For this reason, we investigated the potential role of this receptor in a mouse 
model of Pneumocystis murina infection. 
Wild type and DCAR-deficient C57BL/6 mice were infected with P. murina 
organisms via intratracheal instillation. Fungal burden was measured in the 
lung using quantitative Polymerase Chain Reaction. DCAR-deficient mice 
had a significantly reduced burden compared to wild type mice at Day 7 and 
14 post-infection. To identify the immune components involved in pathogen 
clearance in these mice we measured cellular recruitment and cytokine 
production at both early (48 hours) and late (7, 14 and 21 days) time points. 
Flow cytometry analysis showed an increase in alveolar macrophage, 
dendritic cells, inflammatory monocytes, eosinophils and T cell recruitment to 
the lung. While ELISA showed increased levels of IL-1β and IFN-γ at 48 
hours, and later on in infection IL-1β and IL-12p40 levels were also elevated. 
Histology analysis determined the localization of the recruited cells, and 
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interestingly showed an increase in mucus production at day 21 in DCAR- 
deficient mice. 
In conclusion, we have identified DCAR deficiency as a potential driver of 
protective immunity in mice during P. murina infection. This may be 
associated with increased levels of IL-1β in DCAR-deficient mice. 
Furthermore, DCAR may also be important in adaptive inflammatory 
response regulation, as DCAR-deficient mice have increased cellular 
recruitment and mucus production later in infection. The mechanism by 
which the deletion of this receptor affords these mice the ability to efficiently 
clear P. murina remains to be determined. 
 
 
 
Key words: Pneumocystis murina, C-type lectin receptors, Dendritic Cell 
Immunoactivating Receptor 
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Chapter 1: Literature review 
 
1.1. Pneumocystis 
The genus Pneumocystis, consists of three main species of ubiquitous, yeast- 
like extracellular fungi which colonize the alveoli of the mammalian lung (1). All 
three organisms lack attributes of fungal species while concurrently exhibiting 
characteristics of protozoans, which led to the original classification of 
Pneumocystis as being protozoan (2). However, evidence from DNA sequence 
analysis demonstrated that this genus, Pneumocystis, was in fact an 
unconventional fungal genus lacking an in vitro culture system. Hence, it was 
later reclassified as fungi. Further genomic analysis revealed a previously 
unrecognised diversity to be host-specific (2, 3). Pneumocystis carinii, for 
instance, is a rat-specific fungus, whereas pathogenic Pneumocystis murina and 
Pneumocystis jirovecii are found in mouse and man, respectively (4). For over 8 
decades, the pneumonia causing fungal organism in humans, particularly, 
immunocompromised hosts, was referred to as Pneumocystis carinii (2). 
Renaming it to Pneumocystis jirovecii was inspired by Otto Jirovec, who first 
described humans as the reservoir host (2). 
 
Within the primary host, Pneumocystis undergoes different life stages crucial for 
survival (Figure 1). Although this has not yet been fully demonstrated due to the 
inability to culture Pneumocystis in vitro, the two main phases in the life cycle of 
Pneumocystis have been reported, namely cystic and trophic forms 
(5). In the environment, Pneumocystis exists in the cystic form, which has a 
thick-wall (approximately100nm) and reproduces sexually (6). In contrast, 
trophozoites have a thin wall that is approximately 20- 30nm, and are the most 
abundant in the host lung, and hypothesised to reproduce asexually via binary 
fission (5, 7). The most distinctive feature that distinguishes the cyst and troph 
are the macromolecules that make up the cell wall of these two forms (Figure 2). 
While the cystic form is composed mostly of β-glucans, which are easily 
recognised by the innate immune system, trophs lack these important 
glycoproteins (6, 8). The lack thereof is hypothesised to permit immune evasion 
by trophs (9). The cyst is the infective form, as cysts become airborne 
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allowing transmission between the infected and susceptible hosts. The 
infectivity of the cystic form was clearly demonstrated in a study where 
groups of rats were infected with P. carinii in either the trophozoite or cystic 
form. The rats infected with the trophozoites were unable to transfer infection 
to naive nude rats during cohabitation. However, rats inoculated with cysts 
were contagious, successfully transmitting infection to the naive athymic rats 
during cohousing (10). 
 
 
 
Figure 1: Proposed life cycle of Pneumocystis. Cyst and trophozoite are the two well- 
defined phases in the life cycle of Pneumocystis. The intermediate stage (depicted in the 
figure above) leading to mature cysts is known as the precystic phase, where 8 cysts are 
formed. Trophozoites predominate over cysts in the lung alveoli and are said to reproduce 
during acute infection through asexual reproduction. The cystic form is airborne and passes 
from host to host (11). 
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Figure 2: Cell wall components of Pneumocystis cyst and Pneumocystis troph. Both 
the cyst and the troph have N- and O- linked glycans outlying their cell wall A) The 
cyst’s innermost layer is composed of β-glucans but lacks chitins. B) While the inner 
structure of the troph cell wall is composed of proteins and cholesterol but lacks both 
chitins and β-glucans. Adapted from (4) 
 
 
 
1.2. Pneumocystis pneumonia 
Fungal pneumonia, Pneumocystis pneumonia, emanates from failure of the 
immune system to control lung colonisation by Pneumocystis fungi. The global 
burden is estimated to be more than 200,000 of AIDS-related deaths, and more 
than a quarter of this is observed in non-AIDS-patients annually (12). In Sub- 
Saharan Africa the epidemiology is predominantly attributed to the high AIDS 
burden, as risk of infection is correlated with a significant decrease of CD4
+ 
T 
cells (13, 14). Furthermore, the high incidence rate reported in the European 
population and the United States are due to intervention therapies for other 
conditions that tamper with the functionality of the immune system such as 
autoimmune diseases, cancer and organ transplant (15, 16). A similar trend of a 
substantial increase in Pneumocystis cases recently observed in England is also 
attributed to underlying lung diseases (such as cystic fibrosis) and other forms of 
immune suppression excluding HIV (17). 
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1.2.1. Prevalence 
Pneumocystis is among the greatest causes of opportunistic infections 
accountable for the high morbidity and mortality seen in immunocompromised 
individuals (18). Worldwide, Pneumocystis pneumonia is among the top ten of 
the most severe fungal infections affecting immunocompromised individuals 
(19). Prior to the 1980s Pneumocystis was known as the cause of pneumonia in 
premature, malnourished infants, as well as infants who suffered from a 
defective immune system (20, 21). In literature, we find evidence of the first 
cases of Pneumocystis dated back to the era of World War II in European 
orphanages. More Pneumocystis pneumonia cases were later reported in 
orphanages in Iran (22). As time progressed, new treatment strategies for other 
health conditions were introduced. These included the introduction of 
chemotherapy for cancer patients and immunosuppressive drug treatment for 
organ transplant patients. Although the therapies proved beneficial to the 
patients, as they limited the spread of cancer and prevented organ rejection, 
respectively, they also perpetuated the susceptibility of these patients to 
Pneumocystis pneumonia (23, 24). However, at that time there were only 
sporadic cases reported, until the outbreak of HIV/AIDS which introduced a new 
population of Pneumocystis pneumonia candidates (25). Pneumocystis 
pneumonia prevailed during the AIDS epidemic in the early 1980s with high 
incident rate among young homosexual men. Shortly after, Pneumocystis 
pneumonia was acknowledged as an AIDS defining-illness (22). Sub-Saharan 
Africa contributes 70% to the global HIV burden (14), however, this does not 
translate to the prevalence of Pneumocystis pneumonia in these countries. This 
is mainly due to the initiation of highly active antiretroviral therapy (HAART) 
which has had a great impact in reducing the high mortality rates precipitated by 
Pneumocystis in HIV-positive individuals (26). 
 
1.2.2. Diagnosis and Treatment 
The deleterious effect that Pneumocystis pneumonia has on the quality of 
health of immunocompromised individuals can be kept to a minimal through 
accurate diagnosis and timely treatment. The standard procedure is the 
staining of respiratory specimens, the bronchoalveolar lavage fluid (BAL) or 
induced sputum, using Grocott’s staining technique and visualizing the cysts 
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or trophs under the microscope (27, 28). However, the disadvantage 
associated with this method is that accurate diagnosis is reliant on high 
Pneumocystis burden in the lung, consequently imperiling the development 
of severe hypoxia and lung damage in patient (29). Additionally, the 
extraction of BAL fluid or sputum induction, though proven to have a 98% 
sensitivity and accuracy, are very invasive procedures with high cost 
implications and require highly trained staff (30). Therefore, as a means to 
surmount the caveats that accompany the conventional diagnostic 
techniques real-time qualitative polymerase chain reaction (qPCR) was 
developed (31). This method showed the greatest efficacy for early detection 
as it could detect low levels of Pneumocystis, even before disease 
manifestation, whilst also reducing the chances of false-positive results (32, 
33). New diagnostic techniques that are in the pipeline include the serum 1,3-
β-D-glucan (BG) assay, which detects the cysts’ innermost layer of the cell 
wall, 1,3-β-D-glucan, that is recognized by the host (34). Early and accurate 
diagnosis translates to early treatment and a reduced mortality rate. 
 
Trimethoprim-sulfamethoxazole (TMP-SMX) is the first-line drug for the 
treatment of Pneumocystis pneumonia (25, 35). In HIV positive individuals, TMP- 
SMX treatment is administered as a preventative for Pneumocystis pneumonia 
development and is continued until the CD4
+ 
count increases to above 200 
cells/μl (25, 36). Unfortunately, some patients experience an allergic response to 
the primary prophylaxis and are then given the secondary prophylaxis, 
Pentamidine (25, 29). In cases where an individual has had Pneumocystis 
pneumonia, they are given dapsone and atovaquone, which are secondary 
prophylaxis, to prevent reoccurrence (37, 38). Patients that experience mild to 
acute Pneumocystis pneumonia are treated with corticosteroids to alleviate 
chronic inflammation, consequently enhancing patient outcome (35). However, 
there are important limitations that cannot be overlooked concerning the 
invention of novel drugs for patients in constrained settings. These include, the 
route of drug administration, such as intravenous administration, which requires 
hospitalization, in areas that lack well equipped facilities and skilled staff to 
conduct the necessary treatment procedures. This has then prompted 
researchers to employ resources to investigate what 
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happens within the host, both those who control and clear the infection, and 
those in whom disease is exacerbated. 
 
1.3. Immune system 
The immune system is made up of organs, cells and molecules, collectively 
working together in the host mounting a defence against foreign invaders 
(39). The two arms of the immune system utilized against pathogens are the 
innate (natural) and adaptive (acquired) immune responses. The host uses 
these systems to distinguish between self and non-self-antigen, and to also 
recognise a previously encountered pathogen in order to mount a specific 
and a greater immune response (40, 41). 
 
 
1.3.1. Innate immune response to Pneumocystis 
Innate immunity is a very important component of the immune system as its 
primary role is to distinguish between self and non-self-antigens, 
consequently defending the host against invaders (40, 42). The principle of 
self and non-self-recognition is at the core of the innate immunity, and crucial 
for the immune system when deciding how to respond (43). Innate immunity 
is the immediate non-specific response mounted against an infectious 
pathogen (44). This system lacks immunological memory, therefore the 
response mounted is always to the same extent regardless of the number of 
times the same pathogen is encountered (39, 41). 
 
The strategy employed by the innate immune system is that of pathogen 
associated molecular patterns (PAMPs) recognition. PAMPs are repeating 
conserved regions, unique for each group of pathogens that are essential for the 
pathogen to thrive within the host (45). These molecular patterns are then 
detected by pattern recognition receptors (PRRs) expressed by immune cells of 
the host (43, 46). Upon recognition, a release of chemokines and cytokines is 
triggered in an effort to eradicate the infection (47). The different types of PRRs 
utilized by the innate immune system include C-type lectin receptors (CLRs), 
Toll-like receptors (TLRs), NOD-like receptors (NLRs) and Retinoic acid- 
inducible gene (RIG)-I-like receptors (RLRs) (48). Of importance to this 
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study are CLRs, as they have been shown to play a crucial role in mediating 
innate immunity during fungal invasion (49). 
 
CLRs are a group of receptors that effectively tailor antifungal innate immunity. 
These receptors recognise both endogenous and exogenous ligands via 
carbohydrate recognition domains (CRDs) thus initiating an immune response 
(Figure 3) (50). Furthermore, these CLRs can also bind non-carbohydrate 
ligands, such as lipids and proteins via C-type lectin-like domains (CTLDs) (49, 
51). For example, Dectin-1 is a CLR characterised by a single CTLD and ushers 
a host protective immunity through the detection of β-glucans abundant on the 
cell wall of various fungi (52). Conversely, Dectin-2 and Mincle are classical CLR 
possessing a single CRD with a key role in fungal and bacterial recognition 
through various ligands on the surface of these pathogens (49, 53). Dectin-1, 
Mincle and Dectin-2 are all well-known Syk-coupled immunoreceptor tyrosine- 
based activation motif (ITAM)-bearing receptors with an important role in anti- 
fungal immunity. Their signalling mechanism is via the activation of the 
downstream molecule NF-κB through the Card9 pathway (Figure 3) (51, 54). 
The activation of this signalling pathway upon fungal recognition triggers 
proinflammatory cytokine production including IL-6, TNF, and IL-1β, and these 
cytokines have been established as key players in antifungal immunity (39, 55, 
56). Other CLRs that induce intracellular signalling to confer anti-fungal immunity 
include DC-SIGN, Clecsf8 and the mannose receptor (MR) (55, 57, 58). Failure 
of these receptors to control infection triggers a compensatory mechanism which 
manifests through co-signalling. 
 
Co-signalling is a phenomenon which requires the involvement of another 
PRR, such as a TLR or other CLRs, for robust response against pathogens. 
The cross talk between CLRs is an important component of innate immunity. 
Through these interactions these receptors regulate each other to mediate 
protective immunity. For example, Mincle, an important CLR that recognises 
both Pneumocystis and Mtb ligands is regulated by Clecsf8 (59, 60). 
Furthermore, Mincle-deficiency during Pneumocystis infection induces high 
expression of Dectin-1and Dectin-2 which translates into better survival of the 
mice as the disease progresses (60). In contrast, a first report on 
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downregulation of other CLRs during P. murina infection was demonstrated 
in Dectin-2-deficient mice (61). This, however, did not affect pathogen control 
in these mice. Overall, co-signalling of CLRs is an interesting mechanism that 
might be implicated in either enhanced or diminished immune response 
during Pneumocystis infection. 
 
 
Figure 3: C-type lectin receptors that recognise both Pneumocystis and Mycobacterium 
tuberculosis (Mtb) ligands. Various ligands on the cell wall of both Pneumocystis and Mtb 
are recognised by their respective CLRs are shown in the figure above. Interestingly, no 
studies have shown recognition of Pneumocystis by DCAR, however, PIM is the ligand on 
the cell wall of Mtb shown to be recognised by this receptor. Adapted from (62, 63) 
 
 
 
 
1.3.2. Adaptive immune response against Pneumocystis 
In contrast to the innate immune responses, adaptive immune responses are 
specific and highly specialized. The response mounted is robust, much more 
sophisticated and specific to the antigen recognised. The adaptive immune 
response is highly driven by immunological memory which allows for quicker 
elimination of a pathogen that is reoccurring and confers longer lasting 
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protection (41). Adaptive immunity is afforded by two main groups of 
lymphocytes called B cells and T cells. The responses carried out by these 
lymphocytes include antibody responses and cell-mediated immune 
responses, respectively. When B cells encounter a foreign antigen bound to 
a major histocompatibility complex (MHC) presented by an APC, they 
secrete antibodies. In turn, these antibodies serve the function of coating the 
antigen, neutralizing and marking it for ingestion by phagocytic cells (41). B 
cells are also able to present to T cells by first internalizing and processing 
the antigen, and with the expression of an MHC complex and co-stimulatory 
molecules, activate T cells (62). Sequentially, T cells respond by either killing 
the pathogen directly, through killing the infected host cell, or send signals to 
other cells of the immune system (such as macrophages) for phagocytosis of 
the pathogen (39, 41). 
CD4+T cells are a major part of cell-mediated immunity against 
Pneumocystis. Hence, a decline in the number of CD4+T cells leaves HIV 
positive patients vulnerable to infection (63). When CD4+T cells are activated 
by an antigen they differentiate into subtypes including T helper type 1 (Th1), 
Th2, and Th17 effector T cells (64). These cells are characterised by their 
signature cytokines which perform unique effector functions during infection. 
Th1 cells primarily produce Interferon gamma (IFN-γ) as their signature 
cytokine, along with other pro-inflammatory cytokines (such as TNFα, TNFβ 
and IL-2). A Th1 response drives the production of IgG2a antibody, which 
confers protection against intracellular pathogens. Conversely, Th2 response 
signal against extracellular pathogens by producing interleukin 4 (IL-4), IL-5, 
IL-13, and IL-25, and promote the production of IgG1 and IgE antibodies 
(65). Studies have illustrated the importance of maintaining a balance 
between Th1 and Th2 responses during fungal infection, as excessive of 
either responses may have detrimental effects in the infected host (66). 
Another group of T cells, Th17 cells with a signature cytokine IL-17, were 
shown to play a compensatory role by enhancing the host immune response 
against pathogens (such as fungi and bacteria) when the Th1 and Th2 
responses are not efficient at clearing the infection (67). 
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1.4. Dendritic cell immunoactivating receptor 
C-type lectin receptors are the key players in early response against 
Pneumocystis infection. While inhibition of these receptors in mice promotes 
an increased fungal burden in the lungs, the mice eventually do clear the 
infection (61, 68). For example, Dectin-1- and Mincle-deficient mice present 
with high Pneumocystis burden and cannot efficiently produce cytokines, but 
the disease outcome is similar to that of wild type mice (19, 69). This implies 
that, although CLRs have an apparent role in controlling the fungal burden in 
the lung, clearance of the infection does not exclusively depend on CLRs, 
other PRRs and cells of the immune system are likely to be involved (61, 70). 
Other CLRs that have been shown to contribute to the resolution of fungal 
infections include Dectin-2 and DC-SIGN (49, 55). 
The dendritic cell immunoactivating receptor (DCAR) is a new receptor, 
recently shown to function in Mycobacterium tuberculosis recognition (Figure 
3) (71). DCAR is a type II CLR belonging to the dendritic cell immunoreceptor 
family (DCIR) (72). It is highly expressed by a distinguished subtype of DCs, 
antigen presenting cells and other myeloid cells (73, 74). A study by Kanazawa 
(2003) showed the various tissue sites at which this receptor is expressed, with 
the lung and spleen being the primary sites for this receptor, and low expression 
were observed in the skin and lymph nodes (75). Other CLRs that form part of 
the DCIR family include dendritic cell immunoinhibiting receptor (DCIR), Dectin-2 
and blood DC antigen-2 (BDCA-2) (73, 76). DCAR and DCIR are said to be 
homologous due to similarities in their extracellular lectin domain, however, they 
possess different short cytoplasmic tails (75). DCAR bears an immunoreceptor 
tyrosine-based activating motif (ITAM), while DCIR is characterized by an 
inhibitory immunoreceptor tyrosine-based inhibitory motif (ITIM) (75, 77) . These 
receptors are expressed simultaneously on monocyte-derived inflammatory cells 
conferring a balanced signal at the surface of these cells. DCAR possesses a 
82% amino acid sequence homology with Dectin-2, which is a classical CLR with 
a key role in antifungal immunity (72, 78). Of importance to note is that DCAR 
induces activating signals through its association with the FcR -γ chain, an 
association that has been noted to be crucial in other CLRs such as Mincle for 
protective immunity 
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during fungal infection (75, 79). In a tuberculosis (TB) mouse model of 
infection it was demonstrated that DCAR utilizes the Spleen tyrosine kinase 
(Syk)/Caspase recruitment domain family member 9 (CARD9) pathway to 
induce a Th1 immune response which is of priority during an active TB 
infection (71, 80). Interestingly, the role of this CLR has not yet been shown 
in Pneumocystis infection. Therefore, our aims were to determine disease 
progression in DCAR-deficient mice and analyse the early and adaptive 
immune responses that associate with the observed phenotype. We further 
wanted to assess the effect of cohousing experimental animals prior to 
experimentation. 
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2.1. Mice 
Chapter 2. Materials and Methods 
 
The following mice were used for experiments: 
 
• Wild type (C57BL/6 background) (The Jackson Laboratory strain) 
• Clec4b1-/- (C57BL/6 background) (71) 
The mice were kept in individually ventilated cages (IVCs) under special 
pathogen free conditions at the Animal Unit facility located at the Chris Barnard 
Building, at University of Cape Town. The two strains of mice were cohoused in 
frequently cleaned cages with sufficient food and water supply. Only female mice 
were used for the purpose of this study, aged between 8-12 weeks. The mice 
were monitored daily for symptoms of adverse effects following infection and to 
ensure that they were not experiencing any distress or discomfort. The dendritic 
cell immunoactivating receptor (DCAR) knockout mice (Clec4b1
-/-
) 
generated using Platinum TALEN (81) as previously described (82) were 
provided by our collaborators from Japan (Sho Yamasaki) and were kept at 
quarantine during the period of the study. This study was authorized by the UCT 
Faculty of Health Sciences Animal Ethics committee (015/046). 
 
2.2. Genotyping 
DNA extracted from DCAR-/- mice tail sections was used to confirm the 
genotype by polymerase chain reaction (PCR) analysis. To extract DNA, the 
mice tail clippings were incubated overnight at 56˚C in 500µl lysis buffer. 
After centrifugation at 10 000 rpm for 10 min, the supernatant was removed, 
and DNA was precipitated by isopropanol. After centrifugation at 10 000 rpm 
for 6 min, the pellet was washed with 70% ethanol and allowed to air dry. The 
DNA pellet was then resuspended in dH2O and used for genotyping by PCR. 
A set of primers that were used in PCR to confirm Clec4b1 gene deletion 
were purchased from the Department of Medical Biochemistry at the 
University of Cape Town. 
 
The following primers were used for the purposes of genotyping DCAR
-/- 
mice: 
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F: GGCTATCTCTGTGGTATTTAGCTC 
R: CCCTACCTTGTAGCTGTCTT 
The T100™ Thermal Cycler (BioRad) was used for PCR amplification of the 
Clec4b1 gene using conditions set out in Table 1. MgCl2, PCR buffer and 
Taq polymerase were purchased from Vector Laboratories (UK), and the 
dNTP stocks were obtained from Promega, Madison, United states. 
 
Table 1: Amplification conditions for the Clec4b1 gene 
 
 Temperature ˚C Time (seconds) 
1. Initial denaturation 94 180 
2. Denaturing 94 30 
3. Primer annealing 60 30 
4. Extension 68 30 
5. Final extension 72 300 
6. Repeat step 4 ∞ 
 
Electrophoresis of the DNA from each sample was carried out on 1.6% 
agarose gels with 1x Tris borate ethylene di-amino tetra acetic acid (TBE) as 
the buffer. The gel was run at 180 Volts for 90 minutes and a 1 kb DNA 
ladder (Promega, Madison, United States) was used to determine the DNA 
size. The expected band size was 144bps, as was observed on the agarose 
gel (Figure 3.1). 
 
 
2.3. Infection of mice with Pneumocystis murina 
Pneumocystis cannot be cultured, therefore, Pneumocystis was propagated by 
infecting Rag-1-deficient mice with 5x10
5 
cysts in 100µl sterile LPS-free PBS 
(gibco by life technologies) via intratracheal instillation. Lungs were then 
harvested and kept in a -80 degrees Celsius freezer as stock. To prepare the 
inoculum, we isolated the cysts and trophs from infected RAG-1-deficient mouse 
lungs (stored at -80 °C) by mashing it through a 70µm sieve in 4ml of phosphate 
buffer saline (PBS). After centrifugation at 2000 rpm for 10 min, the supernatant 
was removed, and the pellet was resuspended in 1ml of PBS. To 
15  
count the cysts on a Fisher brand microscope slide we did a 1:10 dilution of 
the sample in PBS, and 5µl of the diluted sample was placed on the slide and 
left to air dry before staining. Diff-quick (Difco, Detroit, Mich) staining 
technique was used, which stains both cysts and trophs. After staining the 
sample, the slide was rinsed under running tap water and left to air dry before 
counting cysts under the x100 oil immersion lens of a light microscopy. To 
differentiate between cysts and trophozoites under a light microscope we 
identify the presence of one lucid nucleus, which is a phenotypic 
characteristic of trophozoites. While cysts are identified by the presence of 
multiple intracystic bodies (between 4 to 8 nuclei). To infect mice, we used a 
final concentration of 2x105   cysts in 100µl of   the inoculum, which   we 
calculated using the following equation: πr where π=3.14 and r =No of 
cysts/2 and diluted with required volume of PBS. Both the control and 
experimental mice were co-housed for 2 weeks before infection, unless 
stated otherwise. On the day of infection, the mice were intraperitoneally 
injected with ketamine and xyalizine (80mg/kg and 16 mg/kg, respectively) 
for anaesthesia, then suspended vertically from their front incisors on suture 
wire. In order to gain access to the trachea and allow the mice to breath while 
anesthetised, the tongue was carefully extended to the left. Thereafter the 
mice were infected via intratracheal instillation with 2x105 of the inoculum. 
Daily monitoring of mice was initiated post infection, until the pre-determined 
time points of sacrifice. Those involved in the study were accredited by the 
South African Veterinary Council for all animal experimental procedures. 
 
2.4. Confirmation of death by cardiac puncture 
At each sacrificial time point, halothane (5% in air) was used in an enclosed 
container to euthanize the mice. Mice were then placed dorsally on a board 
and 70% ethanol was sprayed to sterilize the area below the sternum before 
needle insertion. A 1ml insulin needle was inserted on a 20° angle just left of 
the xiphoid process. The syringe plunger was slowly retracted while gently 
moving the needle forward, and once the blood started flowing into the 
syringe, the needle was held steadily until blood 400µl to 600µl of blood was 
collected into a 600µl BD microtainer gel separation tube. 
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2.5. Collection of lungs 
At the set time points following infection mice were sacrificed using halothane 
and cardiac puncture. They were then sterilized with 70% ethanol before 
opening them up. The ventral midsection was incised up to the neck region to 
remove the ventral skin. Another incision was made on the peritoneum from 
the lower abdomen towards the cervical region to expose the organs. The 
lungs were exposed by the cutting and removal of the rib cage. As the lung of 
a mouse is divided into five lobes, each lobe was aseptically collected into its 
respective collection tube. For histology purposes the left lobe was fixed in 
4% formalin in PBS, the two right lobes were collected into 500µl of PBS + 
protease inhibitor for the tissue cytokine ELISA and bicinchoninic acid (BCA) 
assays, 800µl of trizol was used for collecting one lobe for RNA extraction, 
and the last lobe was removed and collected into 1ml of dulbecco modified 
eagle medium (DMEM) + 2% fetal bovine serum (FBS) for flow cytometry. All 
samples were immediately homogenised and stored at -80, excluding the 
flow cytometry samples which were processed, stained, fixed on the day of 
the kill and acquired within 7 days. 
 
2.6. Quantification of Pneumocystis 
 
 
RNA extraction 
 
Lung samples collected in Trizol which were homogenized and stored at -80 
°C were thawed at room temperature (RT). Using chloroform each sample 
was separated into phases of DNA, protein and RNA by centrifugation at 12 
000 rpm for 10 min. The top aqueous layer was transferred into separate 2ml 
eppendorf tube and isopropanol was used for RNA precipitation. The pellet 
was then washed in 1ml 75% ethanol following centrifugation for 10 min. The 
pellet was left to dry before adding 50µl of dH2O, and the RNA concentration 
and purity were read on the Nanodrop ND-1000 Spectrophotometer prior to 
making cDNA. 
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cDNA synthesis 
 
All our RNA samples were normalized to 1µg per reaction to compensate for 
contaminating mouse RNA present in the samples. From each sample 1µg of 
RNA was converted to cDNA using the iScript cDNA synthesis kit from Bio- 
Rad, as per the manufacturer’s instructions. The kit contains 5X iScript 
reaction mix, iScript Reverse Transcriptase and Nuclease-free water. The 
required volume of each reagent was added, and DNA was synthesized 
using the following conditions: 
 
Table 2: cDNA synthesis conditions 
 
 Temperature ˚C Time (minutes) 
1. Priming 25 5 
2. Reverse transcription 46 20 
3. Reverse Transcription 95 1 
 incubation 
 
qPCR 
 
To quantify Pneumocystis the small subunit rRNA gene of P. murina was 
targeted using specific primers (described below). The starting concentration 
of our arbitary standard was 108  copies and a series of 10-fold dilution were 
performed w i t h  the lowest standard at 10-3copies.  The SsoAdvanced 
quantitative RT-PCR (qRT-PCR) universal probes master mix was prepared 
as detailed in the Table 3 below. In a 96 well PCR plate we added 15µl of the 
Master mix followed by 5µl of the cDNA and covered with a clear PCR plate 
seal before centrifuging the plate at 1200 rpm for 1min. After centrifugation 
the reaction was ran on the Real time PCR machine. 
 
SSU primer and probe sequences are as follows: Forward 
5’-CATTCCGAGAACGCAATCCT-3’; Reverse 5’- 
TCGGACTTGGATCTTTGCTTCCCA-3’; FAM-Probe: 5’- 
TCATGACCCTTATGGAGTGGGCTACA-3’ 
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Table 3: PCR Master Mix ingredients and volumes 
 
PCR Master Mix Volume (µl) 
2x Supermix 10µl 
40x Primer mix 0.5µl 
H2O 4.5µl 
 
 
2.7. Flow cytometry 
Immediately after the collection of lungs on sacrificial day the lungs were cut into 
small pieces and then incubated at 37°C for 90 min in digestion buffer (Appendix 
A). After incubation the lungs were minced through a 70µm cell strainer before 
centrifugation at 1500 rpm for 10 min. The precipitate of cells was then removed, 
and the red blood cells were lysed using Red blood cell lysis buffer (RBC) 
(Appendix A) at room temperature for 1 min after which 5ml of PBS was added 
to stop the reaction. Subsequently, FACS buffer (Appendix 
A) was used for resuspension of cells after the second wash with PBS. 
Trypan blue was then used to stain 20µl from each sample and the cells 
were counted with a haemocytometer under a light microscopy. The 
remaining cells were then stained with 25µl of lineage-specific cell-surface 
markers (table 4) and incubated in the dark for 30 min on ice. FACS buffer 
was then added to stop the staining process after which the cells were fixed 
before filtering and acquiring on a FACS LSRII (Beckton Dickinson) flow 
cytometer using FACS Diva version 6.0 (Beckton Dickinson). All samples 
were analysed using Flowjo V10 software (Treestar, USA). 
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Table 4: Flow cytometry Antibodies 
 
Antibody Clone name Source 
Antigen presenting cells markers 
APC Rat Anti-Mouse Ly6G 1A8 BD Pharmingen 
Alexa Fluor® 700 Hamster Anti- 
HL3 BD Pharmingen 
Mouse CD11c 
V450 Rat Anti-Mouse CD11b M1/70 BD Horizon 
APC-Cy 7™ Rat Anti-Mouse Siglec f E50-2440 BD Pharmingen 
Rat mAb to Neutrophil (7/4) (FITC) GR288279-11 Abcam 
BV510 Rat Anti-Mouse CD45 30-F11 BD Horizon 
PE/Cy7 Anti-Mouse F4/80 BM8 Biolegend 
   
T cell markers 
BV421 Hamster Anti-Mouse CD3e 145-2C11 BD Horizon 
PE Rat Anti-Mouse CD44 IM7 BD Horizon 
FITC Rat Anti-Mouse CD8a 53-6.7 BD Horizon 
Alexa Fluor® 700 Rat Anti-Mouse 
RM4-5 BD Horizon 
CD4 
 
 
2.8. Enzyme linked immunosobernt assay 
Cytokine production levels in lung tissue were measured using an ELISA kit as 
per manufacturer’s instructions (BD OptEIA). Cytokines of interest that were 
measured include, TNF, IL-1, IFN-γ, IL-12p70, IL-12p40, IL-6, and IL-10. Briefly, 
96 Maxisorb Nunc (Nalge Nunc International, Naperville, IL, USA) well plates 
were coated with 100μl/well of Capture antibody diluted in coating buffer 
(Appendix A) and left to incubate at 4°C overnight. The plates were then washed 
3 times with washing buffer (Appendix A) and blocked with blocking buffer 
(Appendix A) 200µl/well and incubated at RT° for 1 hour. While the plates were 
incubating, the recombinant standard was prepared according to 
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the manufacturer’s instructions (starting concentration Table5). After 
incubation period was completed, the plates were washed 3 times, and100µl 
of the recombinant standard was added to appropriate wells in 2-fold serial 
dilutions. Samples were also added, and the plates were incubated at RT° for 
2 hours. The plates were again washed with a total of 5 washes and the 
Detection antibody + Enzyme reagent (Streptavidin-horseradish peroxidase 
conjugate) were diluted in Assay diluent and 100µl/well was added to each 
plate and incubated at RT° for 1 hour. At the end of incubation, the washing 
step was repeated with a total of 7 washes, and 100µl/well of PNP substrate 
solution (4-nitrophenyl disodium salt-hexahydrate) (1mg/ml in Substrate 
Buffer, Appendix A) was added and plates were developed at RT° in the 
dark. Thereafter, 50µl/well of sulfuric acid was added to stop the reaction and 
the absorbance was read at 450nm within 30 min of stopping the reaction 
using a VERSA max Tunable Microplate Reader (Molecular Devices 
Corporation, California, United States) and data analysis was achieved using 
Soft Max Pro Version 4.3 Software (Molecular Devices Corporation, 
California, United States). 
21  
Table 5: Cytokine ELISA kit Antibody dilutions/ Recombinant 
concentration 
 
 
Cytokine 
Capture Detection Enzyme 
Standard  
Source Concentration 
Antibody Antibody Reagent 
 
TNFα 1:250 1:1000 1:250 
4ng/ml BD 
Biosciences 
IFN-γ 1:250 1:250 1:250 
2ng/ml BD 
Biosciences 
IL-1β 1:250 1:500 1:250 
2ng/ml BD 
Biosciences 
IL-12p40 1:250 1:1000 1:250 
1ng/ml BD 
Biosciences 
IL-12p70 1:250 1:250 1:250 
4ng/ml BD 
Biosciences 
IL-6 1:250 1:500 1:250 
1ng/ml BD 
Biosciences 
 
 
 
2.9. Histology 
Lung samples collected in 10% Formalin from mice at pre-determined time 
points were sent to the laboratory at the Department of Surgery, Groote 
Schuur Hospital. A qualified technician sectioned and embedded the lung 
sections in wax. The process includes dehydration and rehydration, as 
detailed in Table 6 and 7 below. 
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Table 6: Dehydration 
 
 Number of changes Length of procedure 
70% Alcohol 1 30 minutes 
96% Alcohol 2 45 minutes 
100% Alcohol 4 45 minutes 
Xylol 2 60 minutes 
Wax (55°C to 60°C) 2 45 minutes 
 
The lung samples were embedded in wax and then trimmed into thin 
sections. The thin tissue sections were then floated in a warm water bath 
after which the sections were placed onto glass slides and incubated at 37°C 
for 2-18 hours to remove the wax. Tissue rehydration process for staining is 
shown below in Table7. 
Table 7: Rehydration 
 
 Number of changes Length of procedure 
Xylol 1 3 minutes 
Xylol 2 1 minute 
Absolute Alcohol 2 1 minute 
96% Alcohol 2 1 minute 
70% Alcohol 1 1 minute 
Water 1 1 minute 
 
The rehydrated tissue was stained with either the Grocott’s Methenamine 
silver stain (GMS) (used to stain fungal organisms), or Periodic acid–Schiff 
(PAS), or Haematoxylin and eosin stain (H&E). Photomicrographs were 
captured using Nikon DS-Ri2 high performance camera and analysed with 
the NIS Elements AR 4.30.01 imaging software. 
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2.10. Statistics 
Statistical comparison between two groups was performed using student’s t- 
test, with a two-tailed distribution, unless stated otherwise. All statistical 
analysis was completed using Graph Pad Prism (version 6) and data is 
demonstrated as the mean ± SEM. For all tests, a p-value< 0.05 was 
considered statistically significant. 
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Chapter 3. Results 
3.1. Confirmation of Dendritic Cell Immunoactivating 
Receptor (DCAR) deletion in mice 
DCAR-deficient mice were genotyped to confirm the deletion efficiency of the 
Clec4b1 gene (Figure 3.1). This was done by digesting tail sections from 
mice and extracting DNA for PCR analysis. The expected band size was 
144bps, as was observed on the agarose gel (Figure 3.1). Lanes 2 to 10 
showed bands of 144bp, which were the expected band sizes from mice with 
DCAR deficiency. DNA extracted from WT mice served as a positive control 
and showed a band size of 150bp (lane 11). We added H2O to the PCR 
reaction as a negative control (lanes 12 &13) and no bands were observed. 
 
 
 
 
 
 
 
 
Lanes: 1 2 3 4 5 6 7 8 9 10 11 12 13 
 
 
 
 
300bp 
200bp 
100bp 
 
 
 
 
 
Figure 3. 1: Genotyping of DCAR-deficient mice. DNA extracted from DCAR-/- 
mouse tails was amplified by PCR and ran on electrophoresis agarose gel to 
visualise the band size. Lanes 2 to10 show bands at 144bp which represents DCAR- 
/- mice. Lane 11 shows a band at 150bp, which is the expected size for WT mice 
which served as our positive control. Lanes 12 and 13 show no bands as water was 
used as a negative control 
H2O H2O 
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3.2. Pneumocystis murina standard 
 
Pneumocystis species are not viable in culture. Therefore, to quantify the 
fungal burden we established a qRT-PCR assay. Under the guidance of 
Georgia Schäfer, we made a standard using a plasmid (pGEM-T-SSRNA1.1) 
containing the mitochondrial RNA (mtRNA) insert of P. murina sent to us by 
Jay Kolls (USA). The pGEM-T-SSRNA1.1 spotted on filter was transformed 
into Escherichia coli (E. coli) TOP10 cells. Colonies were then selected for 
sequencing. After digesting 4ug of pGEM-T-SSRNA1.1 with the restriction 
enzyme Not I for release of the insert, the product was then run on a 1% 
agarose/TAE gel to check for complete digestion with a 3kb band size 
expected (Figure 3.2 A). After purification of the linearized plasmid, a final 
concentration of 168ng/ul was achieved. An amount of 1.5ug of the linearized 
plasmid was used for In Vitro Transcription (IVT). The product was then run 
on 1.5% agarose/MOPS gel to control for a single product and confirm the 
size of the IVT product (Figure 3.2 B). 
A B 
 
 
Figure 3. 2: Pneumocystis murina standard. Pneumocystis quantification by qPCR requires 
a standard of known concentration. Therefore, a plasmid containing P. murina mtRNA was 
transfected into E. coli bacteria. A) After complete digestion of the plasmid, linearization 
was confirmed on an agarose gel. B) The IVT product was transcribed into RNA, run on a 
gel, and the IVT product was stored at -80 C  at a concentration of 47.2ng/ul. 
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3.3. DCAR deletion enhances P. murina clearance 
CLRs have an important role in Pneumocystis recognition, potentially 
contributing to clearance (60, 69). Previously, Dectin-1, a phagocytic cell 
specific CLR, has been shown to facilitate protective immunity during 
Pneumocystis infection (69). Therefore, we sought to investigate the role of 
DCAR, a newly described dendritic cell receptor, during P. murina infection. 
To carry out this experiment, both the experimental and control mice were co- 
housed for 2 weeks prior to infecting them with 2x10
5 
P. murina organisms. 
Lungs were harvested at pre-determined time points and various immune 
parameters were measured to assess disease progression and pathology. Using 
qPCR, we were able to detect and quantify P. murina in the lungs of infected 
mice. Shown in Figure 3.3A is a graphical representation of P. murina 
quantification, where we observed reduced fungal burden in DCAR
-/- 
mice in 
comparison to WT mice, at both day 7 and day 14 post-infection. We further 
used Grocott’s methenamine silver (GMS) staining to visualise P. murina cysts in 
mouse lung tissue. Although GMS stain only detects the cysts and not the 
trophic form of P. murina, the microscopy visualisation showed similar fungal 
burden as the  PCR  quantification,  with  DCAR
-/-   
mice  exhibiting  a  lower P. 
murina burden compared to WT mice (Figure 3.3B). Both mouse strains had 
cleared the infection by day 21 post-infection (Figure 3.3A&B). Figure 3.3C 
shows representative GMS stained histology pictures taken from WT lung tissue 
samples at 40X magnification for clear visuals of clusters of cysts. 
28  
A (i) (ii) 
 
 
 
B   
D7 D14 D21 
 
 
 
 
 
 
 
 
 
 
 
 
C Representative photomicrographs of WT mice 
 
Figure 3. 3: Pneumocystis murina burden quantification and visualisation in DCAR-/- 
and WT mice. A) P. murina was quantified using qRT-PCR at the pre-determined 
timepoints (i & ii are two independent repeat experiments). B) Representative 
photomicrographs of P. murina in lung tissue stained with GMS (20X magnification). C) 
WT representative pictures taken 40X magnification (single cysts and clusters of cysts 
indicated by solid black arrows and open black arrows, respectively). The results shown 
indicate the mean ±SEM of five mice per group for all time points. Significant differences 
(* p<0.05, **p<0.01) were determined using the unpaired one-tailed and two-tailed 
student’s t tests for figure 3.3 A (i) and (ii) respectively. 
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3.4. Localisation of Inflammatory cells 
 
Lung samples that were collected in 10% formalin were sectioned and 
embedded onto slides for histopathology analysis. Tissue samples were then 
stained with Haematoxylin and eosin (H&E) stain, which stains nucleated 
cells with a dark purple colour, to assess the localisation of cells in the lungs 
of P. murina infected mice. At day 7 there were no apparent differences 
between the DCAR-/- and WT mice. By day 14 there was seemingly greater 
cell infiltrates into the lungs of DCAR-/- mice compared to WT mice (Figure 
3.4&B), however, when we quantified free alveolar spaces, the percentage 
difference was comparable between DCAR-/-  and WT mice (Figure 3.4C).  A 
greater accumulation of inflammatory cells was observed around the 
peribronchiolar regions of DCAR-deficient mice 14 days post-infection. When 
looking at a later time point, we noted that an influx of cells was still 
pronounced at day 21 in DCAR-/- mice, which had subsided in WT mice 
(Figure 3.4A&B). Furthermore, cells were markedly dispersed on the alveolar 
regions of DCAR-/- mice 21 days post-infection compared to WT mice, whose 
alveolar spaces were clear of cell infiltrates. To confirm our observations of 
the microscopic analysis, we further quantified free alveolar spaces and 
these results validated the histologic analysis (Figure 3.4C). 
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Figure 3. 4: Determining cellular infiltration by H&E staining. Mice infected with 2x105 P. 
murina were euthanized at D7, 14 & 21. A) H&E stained photomicrographs showing an 
overview of lung tissue cross-sections (4X magnification). B) Lung sections magnified at 
20X for clear representation of cell. C) Representative graph of quantification of free 
alveolar spaces represented as percentages. An unpaired two-tailed student’s t test was 
done.   
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3.5 Cellular response during P. murina infection 
To assess the immune cells that were recruited during P. murina infection, 
mice were euthanised and lungs harvested and processed (outlined in 
materials and methods) for FACS analysis. After single cell suspensions 
were prepared, samples were stained with the following antibodies: 
Myeloid cell panel: Ly6G (APC), CD11c (Alexa Fluor 700), CD11b (V450), 
Siglec-F (APC-Cy 7), 7/4 (FITC), CD45 (BV510), F4/80 (PE/Cy7) (Figure 
3.5A). 
T cell panel: CD3 (BV421), CD4 (Alexa Fluor 700), CD8 (FITC), CD44 
(PE/Cy7) (Figure 3.5B) 
Samples were acquired using a flow cytometer and analysed by FlowJo 
software. Single cells were gated on to rule out doublet populations and AMs 
were identified as Siglecf+ F4/80+. Markers used for DCs were 
CD11c+Siglecf -7/4-, inflammatory monocytes were identified as CD11b+ 
7/4+, neutrophils were identified as Ly6G+CD11C-, and eosinophils were 
marked as Siglecf+7/4-. 
Alveolar macrophages in conjunction with other immune cells, such as DCs and 
neutrophils, form part of the host’s immediate response during P. murina 
infection (3). Therefore, the observed reduced fungal burden in DCAR
-/- 
mice 
(Figure 3.3) propelled us to determine cells that were involved in the initial host 
response post-infection. We observed an increase in AMs along with DCs in 
DCAR
-/- 
mice at day 7 compared to WT mice (Figure 3.6A). There was also a 
trend towards an increase in neutrophils in DCAR
-/- 
mice, however this increase 
was not statistically significant (Figure 3.6A). Interestingly, although detected in 
low levels  7   days  post-infection,  eosinophils  and  inflammatory  monocytes 
showed an increased trend in DCAR
-/- 
mice at day 7. At day 14 a trend of higher 
cellular infiltration in DCAR
-/- 
mice was maintained, however, these observations 
were not statistically significant. A similar trend observed in the total number of 
cells translated to the percentage representation of our myeloid cells of interest, 
with a significant decrease in AMs, DCs and inflammatory monocytes at day 21 
in DCAR-deficient mice (Figure 3.6B). 
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Figure 3. 5: Gating strategy for myeloid cells and lymphocytes. Lung cells from WT and 
DCAR-/- mice were isolated and labelled accordingly. A) By gating from the myeloid 
population, we identified: AMs (Siglecf+F4/80+), DCs (CD11c+Siglecf-7/4-), neutrophils 
(Ly6G+CD11c-), Inflammatory monocytes (CD11b+7/4+) and eosinophils (Siglecf+7/4-). B) T 
cells were characterised as either activated CD4 T cells or CD8 T cells (CD3+ CD44+). 
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Figure 3. 6: Cellular responses post P. murina infection was measured by flow cytometry. 
WT and DCAR-/- mice were infected with 2x105 of P. murina and sacrificed at the indicated 
timepoints. The graphs show a comparison between absolute numbers and percentages. 
A&B) Cellular responses in the lungs of both WT and DCAR-/- were measured overtime. The 
results are expressed as mean ± SEM (n = 5 mice/strain per time point). Significant 
differences (* p<0.05, **p<0.01) were determined using the unpaired one student’s t- 
tests. Data shown are representative of two individual repeat experiments. 
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3.6. T cell recruitment during P. murina infection 
T cells, specifically CD4
+ 
T cells, are crucial in protection against Pneumocystis 
infection. Several studies have shown host susceptibility to Pneumocystis 
infection to be rendered by a depletion of these cells (63, 83). We therefore 
analysed T cell recruitment during Pneumocystis infection in mice. As early as 
day 7 post-infection we saw increased CD4
+  
T cells recruitment, as well as 
activated CD4
+ 
T cells (CD4
+
CD44
+ 
T cells) in the lungs of DCAR
-/- 
mice 
(Figure 3.7A). Additionally, we observed high number of CD8
+
 
T cells and activated CD8+ T cells (CD8+CD44+ T cells) in DCAR-deficient 
mice (Figure 3.7A). By day 14 the number of T cells that were recruited into 
 
the lungs were still increased in DCAR-/- mice compared to WT mice, with 
notable statistical differences (Figure 3.7A). Looking at the frequency of T cell 
responses, we saw no significant differences at day 7 in both mouse strains 
(Figure 3.7B).  However,14 days post-infection  a  significant  increase was 
observed in the percentage of all T cell subsets in DCAR-/- mice (Figure 
3.7B). By day 21 T cell responses were comparable between DCAR-deficient 
and WT mice (Figure 3.7A&B). 
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Figure 3. 7: T cell recruitment post P. murina infection was measured by flow cytometry. 
WT and DCAR-/- mice were infected with 2x105 of P. murina and sacrificed at the indicated 
timepoints. A) T cell recruitment in both WT and DCAR-/- mice was determined overtime. 
B) The percentage representations of T cells that were recruited during infection. The 
results are expressed as mean ± SEM (n = 5 mice/strain per time point). Significant 
differences (* p<0.05) were determined using the unpaired one-tailed student’s t- tests. 
Data shown are representative of two individual repeat experiments. 
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3.7. Cytokine production post P. murina infection 
 
Myeloid cells such as alveolar macrophages induce the production of specific 
cytokines for their effective function. Some of the key cytokines that have 
been implicated in enhancing immune response during P. murina infection 
include TNFα and IFN-γ (84). Other proinflammatory cytokines evidently play 
a contributory role in Pneumocystis clearance, include IL-1β, IL-6 and IL-12. 
We therefore sought to determine the cytokine profile exhibited by mice over 
the course of infection. Interestingly, although DCAR-/-  mice showed a trend 
towards an increase in TNFα, IL-1β and IL-6 production as early as day 7, 
these differences were not statistically significant (Figure 3.8A). There were 
no differences noted in the production of IL-12p40 from both WT and DCAR- 
/-mice throughout the experimental time points. The production of IL-10, an 
anti-inflammatory cytokine, was significantly impaired in DCAR-/- mice 7 days 
post-infection, and this trend persisted throughout to the last experimental 
time point (day 21) (Figure 3.8A). 
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Figure 3. 8: Cytokine production from lung homogenates measured by ELISA assay. Mice 
were infected intratracheally with 2x105/100µl of P. murina and cytokine levels were 
detected at D7, D14, & D21. A) Cytokine production determined in WT and DCAR-/- mice. 
The results are expressed as mean ± SEM (n = 5 mice/strain per time point). Significant 
differences (* p<0.05) were determined using the unpaired one-tailed student’s t- tests. 
Data shown represent one individual experiment. 
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3.8. Assessment of Mucus production 
Periodic acid–Schiff (PAS) stain, which detects polysaccharides and 
mucosubstances, was used to determine mucus secretion from hypertrophic 
goblet cells. Goblet cells secrete mucus as a means of clearing lung 
infection, and therefore would not be present in uninfected mice. In contrast, 
excessive mucus production can lead to lung tissue damage. In our study we 
found that DCAR-/- mice secreted mucus at all time points compared to WT 
mice, which only had pronounced production at day 14 (Figure 3.9A). Mucus 
production was sustained in DCAR-/- mice which had waned in WT mice 
(Figure 3.9A). These pictures are representative and for an accurate 
assessment of mucus production, quantification would be required. 
 
 
A 
 
 
Figure 3. 9: Detection of mucus production in lung tissue. Mice infected with 2x105 P. 
murina were euthanized at indicated time points. C) PAS stain was used to assess mucin 
expression (an indication for mucus production). Histology pictures were taken at 20X 
magnification and are representative of two repeat experiments 
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3.9. Immune response 48 hrs post P. murina infection 
Based on our observation of reduced P. murina burden at day 7 in DCAR
-/-
mice, 
we wanted to further investigate whether there was a robust early response. We 
therefore, infected both DCAR
-/-  
and WT mice with 2x10
5  
P.  murina organisms 
via intratracheal instillation and our control mice were treated with PBS only. At 
48 hours post-infection mice were sacrificed, and BAL fluid was collected to 
analyse cell infiltration by flow cytometry and cytokine production by ELISA. 
There were no significant differences in the total number of cells between 
DCAR
-/- 
and WT mice that were treated with PBS (Figure 3.10A), suggesting a 
comparable homeostatic state before infection of these mice. Following infection, 
there were also no significant differences in the number of myeloid cells in 
DCAR-deficient compared to WT mice (Figure 3.10A). However, the percentage 
difference of AMs and DCs was significantly high in PBS treated DCAR
-/- 
mice 
when compared to P.  murina infected DCAR
-/- 
mice, with no apparent 
differences in other cell types (Figure 3.10B). 
We further analysed cytokine profile exhibited by these mice 48 hours post- 
infection. Interestingly, we observed a significant increase in IL-6 production, 
as well as a trend of increased IFN-γ and IL-12p40 levels in PBS treated WT 
mice. Furthermore, there was notably a significant increase in IL-1β levels in 
DCAR-/- PBS treated mice compared to WT mice (Figure 3.11A). 
Overall these data show that the DCAR deletion enhances P. murina 
clearance in mice. This ability is characterised by an early AMs and DCs 
response, which in turn trigger an adaptive immune response. Both CD4+ 
and CD8+ T cells are recruited to the site of infection to carry out their 
effector function throughout the course of infection. Thus, DCAR deficiency 
enhanced inflammatory responses critical for early P. murina clearance. 
However, whether these result in hypoxia or lung injury, as suggested by the 
seemingly low percentage of free alveolar spaces and excessive mucus 
production in DCAR-deficient mice, remains to be determined. 
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Figure 3. 10: Early response in mice at 48 hrs post-infection. BAL was collected from mice 
that were either infected with 2x105 of P. murina or treated with PBS. (i) Innate cell 
responses measured by flow cytometry. (ii) Percentages of cells that were recruited to the 
lungs. Results are expressed as mean ± SEM (n = 6 mice/strain per time point). Significant 
differences (* p<0.05, **p<0.01) were determined using the unpaired one-tailed student’s 
t- tests. Data shown represents one individual experiment 
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Figure 3. 11: Cytokines produced by WT and DCAR-/- mice at 48 hrs post infection. 
BAL was collected from mice that were either infected with 2x105 of P. murina or 
treated with PBS. A) Cytokine production was measured by an ELISA assay. The results 
are expressed as mean ± SEM (n = 5 mice/strain per time point). Significant 
differences (**p<0.01) were determined using the unpaired two-tailed student’s t- 
tests. Data shown represents one individual experiment. 
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3.10. The effect of co-housing in mice 
Host microbiome plays an important role in influencing the immune response 
mounted during pathogenic invasion (85). Moreover, the environment as well 
as diet are essential determinants of the host’s microbial composition (86). A 
passive transfer of microbiota between hosts occurs during co-housing. In 
our initial experiments we observed variability in our results and sought to 
determine the source of this variability. Therefore, cohabitation was 
introduced as means to rule out any external factors that may be of influence 
on the phenotype observed. We compared fungal load in co-housed and 
non-co-housed mice. For co-housing purposes, mice were delivered to the 
experimental facility, biosafety level 2 (BSL2), and marked by ear clippings. 
Thereafter, mice were randomly mixed, while ensuring that each cage had 
both DCAR-/- and WT mice. The mice were then kept together for at least 2 
weeks before infection. Conversely, the non-housed mice were delivered to 
BSL2 and left to acclimatize for at least 2 days before infecting them with P. 
murina. Subsequently after infection with P. murina via intratracheal 
instillation, mice were sacrificed at the pre-determined timepoints (indicated 
in the graphs below). When the P. murina lung burden were quantified by 
qPCR, a significantly higher fungal burden 7 days post-infection in co-housed 
WT mice was observed (Figure 3.12A). However, WT mice that were not co- 
housed prior to infection showed a lower fungal burden (Figure 3.12B). 
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Figure 3. 12: Pneumocystis murina burden measured in co-housed and non-co-housed WT 
mice. P. murina burden was quantified by qPCR at D7, D14, and D21. A) Fungal burden in co- 
housed mice. B) Fungal burden in non-co-housed mice. The results shown indicate the mean 
± SEM of the values of five mice per time point in each group. Significant differences for 
both figure 3.12 A and B were determined using the unpaired two-tailed and one-tailed 
student’s t- tests (*p<0.05), respectively, comparing both D7 and D21 against D14. 
Figure3.12 A is also included in Figure 3.3A. 
 
 
 
 
3.11. Early cellular immune responses in co-housed vs 
non-co-housed WT mice 
Upon the observed differences in fungal burden in co-housed and non-co- 
housed mice, we then wanted to determine if there were differences in 
immune cell response in the two settings. As depicted in the results, at 7 
days post-infection the co-housed WT mice had increased alveolar 
macrophages, neutrophils, and inflammatory monocytes (Figure 3.13A). 
These cells gradually decreased over time, except the alveolar macrophages 
which were again upregulated by day 21. Conversely, non-co-housed WT 
mice showed stunted alveolar macrophage and dendritic cell recruitment at 
day 7 (Figure 3.13 B), however, these cells peaked by day 14 and were 
again reduced by day 21. Neutrophils showed an increased trend at day 7, 
and inflammatory monocytes were significantly higher at day 7 and gradually 
decreased over time (Figure 3.13B). 
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Figure 3. 13: Early responses post P. murina infection in co-housed vs non-co-housed WT 
mice. WT mice were infected with 2x105 of P. murina and sacrificed at D7,14 &21. A) 
Cellular responses in co-housed WT mice. B) Cellular responses in non-co-housed WT 
mice. The results are expressed as mean ± SEM (n = 5 mice per time point). Significant 
differences were determined using the unpaired two-tailed student’s t- tests (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001) comparing both D7 and D21 against D14. Data shown 
represents one individual experiment. Figure 3.13A is also included in figure 3.5A. 
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3.12. T cell recruitment in co-housed vs non-co-housed mice 
We further investigated if the differences observed in innate responses would 
translate into variabilities in adaptive immunity. T cell recruitment was low in co- 
housed WT mice 7 days post-infection, except for the activated CD4
+ 
T cells 
which remained constantly high throughout the course of infection (Figure 
3.14A). CD8
+ 
T cell recruitment peaked at day 14 and was reduced by day 21 
(Figure 3.14A). Additionally, CD4
+ 
T cells were significantly increased at day 21 
in co-housed WT mice. In contrast, non-co-housed WT mice maintained a trend 
of a significantly lower T cells recruitment 7 days post-infection, which increased 
by day 14 and were reduced significantly by day 21 (Figure 3.14B). 
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Figure 3. 14: T cell recruitment post P. murina infection in co-housed vs non-cohoused WT 
mice. WT mice were infected with 2x105 of P. murina and sacrificed at D7, 14 & 21. A) 
Cellular responses in co-housed WT mice. B) Cellular responses in non-co-housed WT mice. 
The results are expressed as mean ± SEM (n = 5 mice/strain per time point). Significant 
differences were determined using the unpaired two-tailed student’s t- tests (*p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001) comparing both D7 and D21 against D14. Data shown 
represents one individual experiment. Figure3.14 A is also included in figure 3.7A. 
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3.13. Cytokine production in co-housed vs non-co-housed 
mice 
To further investigate the differences in immune responses in mice that were 
co-housed and those that were not co-housed we analysed their cytokine 
profiles by an ELISA assay. The differences observed in immune cell 
responses led us to deduce that there would be differences in cytokine 
production in mice that were in the two settings. Overall the cytokine pattern 
was similar between co-housed verses non-co-housed mice (Figure 
3.15A&B). This included the production of IFN-γ, IL-1β and IL-6. Although the 
level of IL-1β production was low in the co-housed mice at day 7, it gradually 
increased over time (Figure 3.15A). While the pattern of TNFα production 
was quite similar for both groups at D7 and D14 (Figure 3.15A&B), co- 
housed mice presented with significantly reduced TNFα at day 21(Figure 
3.15A). TNFα remained elevated in non-co-housed mice until the last 
experimental time point (day 21) (Figure 3.15B). 
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Figure 3. 15: Cytokine production in co-housed vs non-co-housed WT mice. Mice were 
infected with 2x105 P. murina and cytokine production was measured over time. 
A) Cytokine production in co-housed mice. B) Cytokine production measured in non-co- 
housed mice. The results are expressed as mean ± SEM (n = 5 mice per time point). 
Significant differences (* p<0.05, **p<0.01) were determined using the unpaired two- 
tailed student’s t- tests comparing both D7 and D21 against D14. Data shown represents 
one individual experiment. Figure 3.15A is also included in figure 3.8A 
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3.14. Co-housed DCAR mice 
 
Cohabitation influenced fungal burden detected in DCAR-deficient mice, 
particularly, at day 7. When P. murina lung burden were quantified by qPCR, 
DCAR-deficient that were co-housed with WT mice for two weeks prior to 
infection presented with lower fungal burden at day 7 compared to WT mice 
(Figure 3.16A). However, when these mice were kept in separate cages before 
infection, this resulted in DCAR
-/- 
mice presenting with a higher fungal load at 
day 7 compared to WT mice (Figure 3.16B). Owing to these variabilities, all our 
experimental mice were co-housed for two weeks before infection. 
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Figure 3. 16: Pneumocystis murina burden measured in co-housed and non-co-housed mice. 
P. murina burden was detected by qPCR at D7, D14, and D21. A) Fungal burden detected in 
DCAR and WT mice that were co-housed for 2 weeks prior to infection. B) Fungal burden 
detected in non-co-housed DCAR and WT mice. The results shown indicate the mean 
± SEM of the values of five mice per time point in each group. Significant differences (* p<0.05) 
were determined using the unpaired one-tailed student’s t-tests. Data shown represents one 
individual experiment. Figure 3.16A is also included in Figure 3.1A(ii). 
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Overall, the importance of experimental animal cohabitation has been clearly 
demostrated in this study. The differences observed in fungal burden were 
as a result of variations, particularly, in celluar recruitment. Whether these 
differences were as a consequence of microbiome exchange or other 
external factors, such as diet and water, remains to be determined. We do, 
however, show that co-housing is a critical component in animal research 
studies, which aims to standardise the base line of animals prior to infection. 
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Discussion 
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Chapter 4. Discussion, Future studies & Conclusion 
4.1. DCAR in Pneumocystis murina infection 
Pneumocystis pneumonia is a severe form of pneumonia of 
immunocompromised hosts caused by an opportunistic fungus Pneumocystis 
jirovecii. Host immune responses during infection are mediated by, but not 
limited to, C-type lectin receptors (CLRs). These receptors are expressed by 
several myeloid cells of the innate immune system which in turn triggers and 
primes the adaptive immune response. Increasing evidence suggests roles 
for CLRs such as Dectin-1 and Mincle during Pneumocystis infection(60, 69), 
we therefore used an established P. murina mouse model of infection to 
investigate the role of a newly described CLR, Dendritic Cell 
Immunoactivating Receptor (DCAR), during infection. 
Firstly, we confirmed the deletion of the Clec4b1 gene to ensure that the 
mice were globally deficient of DCAR. The behaviour and growth of the mice 
were not altered by the deletion of this gene. This was similarly shown by our 
collaborator; Sho Yamasaki (Japan) (71), where they described the role of 
DCAR in mycobacterial infection. In this study they found that DCAR is an 
important receptor for the mycobacteria ligand Phosphatidyl-inositol 
mannosides (PIMs). DCAR-deficient mice presented with high bacterial 
burden which was characterised by impaired cytokine secretion and minimal 
cellular recruitment (71). 
Considering that DCAR is a CLR and that these receptors are important in 
Pneumocystis recognition, we investigated the role of DCAR by determining the 
disease progression in infected mice. Using qPCR to determine the fungal 
burden we show that DCAR
-/- 
mice are more resistant to infection in comparison 
to WT mice.  The low organism burden detected in DCAR
-/-   
mice over the 
following timepoints: day7 and 14, served as clear indication of an advantageous 
effect of DCAR deletion in mice. This is in contrast with the role of this receptor 
during mycobacterial infection, as described above, where a deficiency in DCAR 
resulted in an increased bacterial load in mice (71). This could be due to the 
differences in the nature of infection between Mycobacterium tuberculosis, which 
is an intracellular pathogen, and P. murina 
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which is an extracellular organism. Interestingly, the role of DCAR is seemingly 
inversely related to that of Dectin-1 during P. murina infection. While Dectin-1 
functions as an important Pneumocystis receptor that initiates host protective 
immunity (69), DCAR appears to predispose mice to infection. Comparably with 
the reports that Dectin-1 deficiency enables mice to clear mycobacterial infection 
more efficiently compared to WT mice (87), DCAR deficiency reduces fungal 
burden and potentially enhances protective immunity in mice. 
Upon P. murina infection inflammatory cells are recruited to the site of infection 
to eliminate the pathogen. In this study we demonstrated the recruitment and 
localisation of cells using the H&E stain. Notably, the stain revealed extensively 
pronounced cellular infiltrates surrounding the peribronchiolar and perivascular 
regions of DCAR-deficient mice, particularly at day 21 post-infection. These 
observations were further supported by the observed decreasing trend of free 
alveolar space in these mice. These are characteristic of an asthmatic 
inflammation which have been previously reported during Pneumocystis 
infection (88). To further delineate the basis for the differences in fungal burden 
observed in DCAR-deficient and WT mice, we determined myeloid cell 
recruitment over the course of infection by flow cytometry. Alveolar 
macrophages are the undisputed key players during Pneumocystis infection as 
they recognize Pneumocystis’ major surface antigen, gpA, through the mannose 
receptor (MR), thereby facilitating phagocytosis and instant killing of the 
organism (89). Furthermore, in immunocompromised patients there exists an 
inverse correlation in Pneumocystis jirovecii burden and the number of 
inflammatory cells present in the lungs (90). Indeed, alveolar macrophages were 
significantly increased 7 days post-infection in DCAR
-/-
mice which corresponded 
to the reduced fungal load in these mice. Therefore, these results reflect a 
central role for alveolar macrophages during P. murina infection, which in our 
study was fostered by the deletion of DCAR. 
Myeloid cells such as alveolar macrophages, in addition to their phagocytic 
function, further serve as antigen presenting cells possessing the ability to 
trigger an acquired immune response when a pathogenic organism is inhaled 
(3). Certainly, CD4+ T cells were the main cells of interest in our study as it is 
well-known that a deficiency in these cells predisposes the host to 
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Pneumocystis infection (63, 91). When analysing the profile of lymphocytes 
recruited into the lungs, we found that the DCAR-deficient mice presented 
with significantly high number of T cells at day 7 post-infection. The 
increased cellular recruitment trend was maintained at 14 days post-infection. 
Additionally, these T cells were in an activated state, suggesting that they 
could efficiently execute their effector function. These results hint to the 
importance of alveolar macrophages, which were significantly higher 7 days 
post-infection, as antigen presenters to T cells. These results further suggest 
a critical role of alveolar macrophages as triggers of adaptive immunity. 
Accordingly, we could postulate that the reduced fungal burden observed in 
DCAR-/- mice was due to the efficient crosstalk between the innate and 
adaptive immune system through alveolar macrophage-T cell interaction, 
which could be accredited to or was enhanced by the deletion of DCAR. 
DCAR deficiency in mice infected with mycobacteria impairs the production of 
proinflammatory cytokines, including IFN-γ and IL-12 (71). The importance of 
these cytokines during Pneumocystis infection is well documented. While IFN- 
γ is not directly linked to Pneumocystis control, it is an important regulator of 
exacerbated inflammatory responses mounted against Pneumocystis thus 
preventing lung pathology (92). Conversely, IL-12 drives cellular recruitment 
and significantly enhances P. murina clearance in immunocompromised mice 
(93). In our study the overall trend of the proinflammatory cytokines was 
increased, however, these differences were of no statistical significance. Of 
important to note was the increased trend of TNFα in DCAR-/- mice at day 7, 
which coincided with the observed increased number of AMs and neutrophils 
in these mice. Although TNFα does not exclusively orchestrate the 
recruitment of AMs and neutrophils to the site of infection, this cytokine has 
however been shown to play a crucial role in this process, and can thus 
further enhance antifungal immunity by these cells (94). 
 
Another cytokine of importance during P. murina infection is IL-1β, which has 
been shown to promote proliferation of Th17 cells in WT immunocompetent 
mice, which are important in antifungal immunity (95). Consistent with these 
reports, IL-1β production levels showed mildly increased trend in DCAR- 
deficient mice at both day 7 and day 14 post-infection and was later reduced. 
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Moreover, IL-1β production is collaboratively induced by neutrophils and 
alveolar macrophages during respiratory viral infection (96), and alveolar 
macrophages were significantly increased in DCAR-/- mice, while neutrophils 
also showed a mild increased trend 7 days post-infection in our study. 
Therefore, taken together our data shows that DCAR deficiency during P. 
murina infection promotes alveolar macrophage response and neutrophil 
recruitment which in turn drive proinflammatory responses through the 
induction of cytokines that drive Th1 and Th17 proliferation, which could 
provide an explanation for the accelerated P. murina clearance. 
 
Inflammatory responses remain important in Pneumocystis clearance, 
however, when not regulated they can cause severe lung tissue injury. This 
phenomenon was clearly shown in IL-10-deficient mice infected with 
Pneumocystis. Upon infection these mice efficiently cleared Pneumocystis, 
however, IL-10 deletion perpetuated inflammation consequently causing lung 
pathology (97). In our study IL-10 production was significantly impaired in 
DCAR-/- mice at day 7, and this trend was maintained throughout the course 
of infection. Coinciding with these diminished levels of IL-10 in DCAR- 
deficient mice was the exaggerated infiltration of cells observed at a later 
timepoint when mice had cleared the infection. The pronounced inflammation 
was further substantiated by a trend of decreased free alveolar spaces 
observed in DCAR-/- at day 21. Taken together, these results thus infer that 
in the absence of DCAR, mice experience increased inflammatory responses 
that enhance pathogen clearance. However, if these lead to a negative 
outcome for lung function remains to be determined. Contrarily, it is possible 
that what we observe in DCAR-/-  mice is the required immune response that 
efficiently clears Pneumocystis. Suggesting that there is a defect in pathogen 
recognition in WT mice, therefore the immune response is not as efficient as 
expected. This is further exacerbated in immunocompromised mice. 
 
Secretion of airway mucus is a defense mechanism employed to entrap foreign 
invading particles and pathogens. During bacterial pneumonia mucus secretion 
is said to prevent disease progression and fosters pathogen clearance (98). The 
latter is true during primary Pneumocystis infection, where mucin hypersecretion 
reportedly plays a defensive role (99). In contrast, 
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progressive mucus hypersecretion has been shown to have a detrimental 
effect resulting in lung diseases such as asthma and chronic obstructive 
pulmonary disease (100). In our study DCAR-deficient mice showed 
pronounced mucus production which was maintained until the last 
experimental time point (day 21). Considering that the fungal burden was 
reduced in DCAR-deficient mice compared to WT throughout the 
experimental period, we could speculate that mucus production in these mice 
played a protective role. However, the seemingly decreased percentage of 
free alveolar spaces observed in these mice may serve as an indication of 
the importance of this receptor as an immune modulator. Therefore, these 
data suggest that DCAR deletion drives mucus production, in turn 
accelerating P. murina clearance in mice, however, DCAR deficiency may 
ultimately be the source of impaired lung function. 
 
 
 
4.2. DCAR in the early host immune response 
Considering that DCAR is an innate receptor, next we looked at the early cell 
recruitment and cytokine production. At 48hrs post-infection we observed no 
differences in the number of alveolar macrophages, dendritic cells, 
neutrophils and inflammatory monocytes in the BAL from both PBS treated 
and P. murina infected WT and DCAR-/- mice. Furthermore, the overall trend 
of cytokine production showed no significant differences in DCAR-/- mice, 
with the exception of IL-6 which was significantly increased in PBS treated 
WT mice.  An interesting observation was that of increased IL-1β in PBS 
treated control DCAR-/-   mice at 48 hrs.  This could suggest that DCAR 
deletion in mice induces IL-1β production, in turn granting our transgenic 
mice an advantage over WT mice in P. murina clearance. However, these 
experiments were only done once and would need to be confirmed. Our 
observations signify the influence of DCAR deletion in early recruitment of 
principal cells, and further imply a potential role for IL-1β as an accessory in 
the first line of defense during P. murina infection. 
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4.3. The effect of cohousing on the immune response 
during P. murina infection 
The assessment of the role that cohabitation has on immune phenotypes and 
disease outcome is an important growing trend in the field of animal research. 
Recent studies have shown that cohabitation can influence phenotypic 
variabilities that may be due to not only genetic modification of mice but also 
external environmental factors such as microbiome (85, 101). Overall, the 
cytokine profiles in our study were similar between mice that were cohoused and 
those that were not. However, there were discrepancies in cellular recruitment 
as our results demonstrated that both the innate and adaptive immune cellular 
profiles were different in cohoused mice compared to those that were not. These 
differences in the immune responses further translated into variabilities in fungal 
burden in mice that were cohoused and those that were not. Our findings concur 
with those reported by Gauguet et.al (2015) whereby susceptibility of mice to 
Staphylococcus aureus was abrogated by 14 days of cohousing (101). 
Therefore, although these experiments were only done once, they guided our 
decision to cohouse all experimental animals. 
 
 
4.4. Future studies 
 
Our data has provided valuable insight into the role of DCAR in Pneumocystis 
infection. However, to fully understand these processes additional questions 
remain. Of interest would be to fully characterise the role of IL-1β in naïve 
DCAR-deficient mice. It has been previously reported that IL-1β promotes IL-17 
production by Th17 cells which are important antifungal T cells (95). Therefore, 
we would repeat the 48 hours experiment to confirm the higher levels of IL-1β in 
PBS only treated DCAR-deficient mice. Additionally, we could analyse the IL-1β 
levels in naïve lung tissue. Here it would be valuable to determine the IL-17 
production in P. murina infected mice. 
We could also further analyse the increased cellular response detected in 
DCAR-deficient mice, later in infection and how this corresponds to the Th2 
responses mentioned. Firstly, we would quantify mucus production as a 
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means of verifying whether the cumulative mucus secretion observed in 
DCAR-deficient mice caused any impaired lung functionality. As mucus 
production is associated with a Th2 response, secondly, we could expand 
our data to include these responses. This could include measuring serum 
antibody production including IgG and IgE. Furthermore, we would look at 
Th2 cytokine production by ELISA and qPCR, specifically IL-13 which is 
associated with mucus production. Furthermore, we could measure IL-5 
production and the associated eosinophil recruitment. Therefore, we would 
include Sirius red staining on our histology sections for eosinophils and also 
determine if there is eosinophilia in our FACS analysis (CD11c-  Siglecf+  cell 
population). Considering that prolonged inflammatory responses can 
eventually lead to decreased lung functionality, we would also determine 
whether the decreased free alveolar spaces observed in DCAR-/- mice at day 
21 results in altered lung capacity using a flexiVent (SCIREQ, Canada, 
currently available at UCT) which measures different parameters in the lung 
including resistance and compliance. 
 
We could also explore alveolar macrophage depletion to determine whether 
an early increase in these cells observed in DCAR-deficient mice is the 
primary source of protective immunity in these mice. Alveolar macrophage 
depletion would be through intranasal administration of Clodronate and we 
would determine P. murina burden by qPCR at an early timepoint. 
Future work will also consider immune suppression of mice through CD4+ T 
cell depletion as a means of establishing whether this receptor is required 
during disease manifestation in immunocompromised hosts. This would be 
based on the observations that the critical role of CLRs such as Dectin-1 and 
Mincle is more apparent during chronic P. murina infection. For example, the 
absence of Dectin-1 renders the mice more sensitive to infection which is 
indicated by high fungal burden in these mice at both day 7 and 14. However, 
these mice clear infection by day 20. In contrast, Dectin-1-deficient mice that 
lack T cells suffer from chronic infection as indicated by the detection of fungi 
four months post-infection (69). Parallel to this, are reports on Mincle- 
deficient mice, that have enhanced  P. murina  burden following CD4+  T  cell 
depletion (60). 
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4.5. Conclusion 
 
We have shown for the first time that DCAR-deficient mice are more resistant 
to P. murina infection. The absence of DCAR led to a significantly low fungal 
burden, which was associated with a significantly higher immune cell 
infiltration into the site of infection. This in turn translated into increased T cell 
recruitment and activation. Furthermore, the cytokine production pattern was 
higher in DCAR-deficient mice, with a notable increase in IL-1β early post- 
infection. However, despite these enhanced immune responses in DCAR- 
deficient mice, infection was eventually controlled in both DCAR-deficient and 
WT mice by day 21. Additionally, DCAR-deficient mice exhibited elevated 
mucus production throughout the course of infection, suggesting that DCAR- 
deficiency likely promotes Th2 responses. Overall, DCAR is a potential driver 
of susceptibility of mice to P. murina infection. However, while the lack of this 
receptor drives protective immunity in mice during P. murina infection, 
characterised by increased alveolar macrophage, DCs, neutrophils, 
eosinophils, inflammatory monocytes and T cell recruitment, it may also be 
important in inflammatory response regulation. The mechanism by which the 
deletion of this receptor affords these mice ability to efficiently clear P. murina 
remains to be determined. 
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Appendices 
Appendix A: Solutions 
Lavage buffer 
 
- 100μl EDTA 
- 50ml 1x PBS 
 
ELISA 
 
1X Phosphate Buffer Saline (PBS) 
 
- 100 PBS Tablets (Thermo Scientific™ Oxoid™) 
- 10L dH2O 
 
 
Coating buffer 
 
- 1X PBS (pH 8.5) 
- Capture antibody (1:250) 
 
 
Wash buffer 
 
- 0.05% Tween 20 (50 ml) 
- 1x PBS (10 L) 
- pH to 7.4 
 
Blocking buffer 
 
- 2% bovine serum albumin (BSA) 
- 0.2g NaN3 
- Make up to 1000ml with 1x PBS and store at 4°C 
 
Diluent buffer 
 
- 1% BSA 
- 0.2g NaN3 
- 1x PBS 
- pH to 7.4 
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HRP Substrate Buffer 
 
- Mix 50% of each TMB Substrate reagent set (BD Fisher Scientific) 
- Substrate reagent A contains hydrogen peroxide 
- Substrate reagent B containing 3,3′, 5,5′ tetramethylbenzidine (TMB) 
in an organic solvent 
Flow cytometry 
 
Digestion buffer 
 
- 120 ml DMEM 
- 0.0226 g Collagenase Type lI, powder (Thermo Fisher Scientific) 
- 31.2 µl DNase I 
FACS buffer 
- 1X PBS 
- 0.5-1% BSA 
- 0.1% NaN3 
Red cell lysis buffer 
 
- 5 mM EDTA 
- 150 mM NaCl 
- 10 % glycerol 
- 25 mM Tris-Cl pH 7.5 
- 0.1 % SDS 
- 1 % Triton –X 100 
- 0.5 % Non idet P-40 
- 0.5 % Deoxycholate 
- 5 mM PMSF 
 
Fixation buffer 
 
- 4g NaOH 
- 100ml 1x PBS 
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- 20g paraformaldehyde 
- Adjust to 7.2 and make up to 1000ml with 
- Filter to sterilize 
 
 
PCR Master mix 
 
- 10 µl 2X SsoAdvanced Universal Probes supermix 
- 0.5 µl 40X primer mix 
- 4.5 µl RNAse free H2O 
 
 
Genotyping 
 
1.6 % agarose gels 
 
- 8g agarose 
- 25ml 10x TBE buffer (0.5x) 
- Make up to 500ml with dH2O 
- Dissolve in a microwave 
 
10 x Stock Tris borate ethylene di-amino tetra acetic acid (TBE) 
 
- 108g Tris (base) 
- 55g Boric acid and 
- 40ml 0.5M EDTA 
- 1000ml of water sterilized through a 0.45μm filter (Millipore Corporation, 
Bedford, USA) and stored at room temperature. 
- 1x TBE = 1:9 (10x TBE: dH2O) 
 
 
Histology 
 
10% formalin 
 
- 100ml formaldehyde (40% w/v formaldehyde solution) 
- 900ml PBS (pH 7.4) 
- Store in a dark bottle 
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Supplementary figure 
 
 
A B 
 
Figure 1: Cellular responses post P. murina infection was measured by flow cytometry. 
WT and DCAR-/- mice were infected with 2x105 of P. murina and sacrificed at the indicated 
timepoints. The graphs show a comparison between absolute numbers and percentages. 
A&B) Cellular responses in the lungs of both WT and DCAR-/- were measured overtime. The 
results are expressed as mean ± SEM (n = 5 mice/strain per time point). Significant 
differences (* p<0.05) were determined using the unpaired one-tailed student’s t- tests. 
Data shown are of an individual experiment that repeats data shown in Figure 3.6. 
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